Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

27.82 -2.78 (-9.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
22 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Nabriva Therapeutics plc (NASDAQ: NBRV) rose 48.8% to $2.20 in pre-market trading. Sinovant Sciences and Nabriva Therapeutics disclosed topline results from Phase 3 trial... 
Via Benzinga
News headline image
Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data ↗
Following the pre-NDA meeting, the FDA has asked Travere Therapeutics Inc (NASDAQ: TVTX) to submit additional data for the sparsentan program in focal... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
Before 10 a.m. ET on Friday, 24 stocks hit new 52-week lows. Noteworthy Mentions: The largest company in terms of market cap to set a new 52-week low was Canadian... 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2021 ↗
Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion. • Cohen... 
Via Benzinga
News headline image
Retrophin Earnings Preview ↗
On Thursday, May 06, Retrophin (NASDAQ:TVTX) will release its latest earnings report. Check out Benzinga's preview to understand the implications. What Are Earnings, Net Income,... 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Snowflake (NYSE:SNOW... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT).... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Yield10 Bioscience (NASDAQ:YTEN) stock increased by 20.74% to $10.36 during Friday's regular session. As of 12:30 EST, Yield10 Bioscience's stock is... 
Via Benzinga
News headline image
70 Biggest Movers From Friday ↗
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
Friday's morning session saw 17 companies set new 52-week lows. Key Facts: Beyond Meat (NASDAQ:BYND) was the largest firm on a market cap basis to set a new 52-... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.